DaVita Inc. (NYSE:DVA) Receives Consensus Rating of “Hold” from Analysts

Shares of DaVita Inc. (NYSE:DVA) have been assigned a consensus rating of “Hold” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $145.60.

A number of brokerages have recently issued reports on DVA. Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Monday, November 3rd. UBS Group reaffirmed a “buy” rating on shares of DaVita in a research note on Monday, December 15th. Wall Street Zen cut shares of DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Truist Financial lowered their price target on shares of DaVita from $140.00 to $128.00 and set a “hold” rating on the stock in a research report on Monday, January 5th. Finally, TD Cowen dropped their price objective on shares of DaVita from $154.00 to $133.00 and set a “hold” rating for the company in a research note on Monday, November 3rd.

Institutional Trading of DaVita

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. boosted its holdings in DaVita by 1,951.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 68,408 shares of the company’s stock valued at $9,089,000 after acquiring an additional 65,074 shares during the period. Norges Bank acquired a new stake in shares of DaVita during the second quarter worth about $32,986,000. Edgestream Partners L.P. purchased a new position in shares of DaVita in the second quarter valued at approximately $6,375,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of DaVita by 132.1% in the second quarter. Arrowstreet Capital Limited Partnership now owns 264,084 shares of the company’s stock valued at $37,619,000 after purchasing an additional 150,318 shares in the last quarter. Finally, Sovran Advisors LLC acquired a new position in shares of DaVita in the second quarter valued at approximately $472,000. 90.12% of the stock is owned by institutional investors and hedge funds.

DaVita Price Performance

DaVita stock opened at $111.43 on Friday. The stock has a market capitalization of $7.87 billion, a PE ratio of 11.48, a price-to-earnings-growth ratio of 0.69 and a beta of 0.99. The business has a 50 day simple moving average of $117.66 and a 200-day simple moving average of $128.98. DaVita has a 12 month low of $108.67 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last released its earnings results on Wednesday, October 29th. The company reported $2.51 EPS for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The company had revenue of $3.42 billion for the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a negative return on equity of 13,370.89% and a net margin of 5.80%.The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $2.59 EPS. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, equities research analysts anticipate that DaVita will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.